View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases.

     

News

FINANCE VIDEO: Regeneus Ltd (ASX:RGS) CEO John Martin Talks about the Licensing of Progenza in Japan

🕔3/9/2017 9:00:20 AM 2084

With the recent announcement of a significant licensing deal with AGC Ltd in Japan, the company is set to build on their platform for the delivery of Progenza to deal with many healthcare issues from arthritis and pain, to genetic disorders.

Read Full Article

Regeneus Ltd (ASX:RGS) Enters Into Collaborative Agreement With Asahi Glass (TYO:5201) To Commercialize Progenza

🕔1/13/2017 2:19:42 PM 2968

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, announced that it has entered into a strategic collaboration and licensing agreement with AGC Asahi Glass (AGC) (TYO:5201), a world-leading manufacturer of glass, chemicals, high-tech materials and biopharmaceuticals.

Read Full Article

Regeneus Ltd (ASX:RGS) FY16 Results Presentation

🕔8/24/2016 9:59:03 AM 1417

Regeneus Ltd (ASX:RGS) are pleased to provide a Company Presentation for the Full Year Results for FY16.

Read Full Article

Regeneus Ltd (ASX:RGS) FY16 Results Announcement

🕔8/24/2016 9:48:39 AM 1497

Regeneus Ltd (ASX:RGS today reported its 2016 financial results and business update. During the year, the company made significant progress on the development of its portfolio of cell-based therapies for the treatment of osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases for the human and animal health markets.

Read Full Article

Regeneus Ltd (ASX:RGS) Appendix 4E and Annual Report 2016

🕔8/24/2016 9:34:59 AM 1312

Regeneus Ltd (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases.

Read Full Article

Regeneus Ltd (ASX:RGS) European Patent to Grant on Stem Cell Secretions Technology for Acne

🕔8/1/2016 10:33:03 AM 2630

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the European Patent Office has decided to grant a patent covering the use of the company's stem cell secretions technology for the topical treatment of acne.

Read Full Article

Regeneus Ltd (ASX:RGS) Q2 2016 Update

🕔7/1/2016 1:30:06 PM 2257

In late May, members of the executive team visited Japan to advance discussions with potential manufacturing and commercial partners for Progenza in Japan. We are pleased to report our meetings went well and we are on track to enter into our first significant partnering agreement in Japan by the end of September 2016.

Read Full Article

Regeneus Ltd (ASX:RGS) Potential Japan Licence Deal a STEP Closer

🕔5/20/2016 11:18:35 AM 2758

Regeneus Ltd (ASX:RGS) announce that an investment report by Edison titled "Potential Japan licence deal a STEP closer" has been published on the Regeneus website.

Read Full Article

Regeneus Ltd (ASX:RGS) Australian Research Council Linkage Grant to Progress Stem Cell Research into Treating Chronic Pain

🕔5/17/2016 9:14:11 AM 3383

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced the Australian Research Council (ARC) had awarded a Linkage Grant of $340,000 to a research consortium that includes Regeneus collaborating with leading researchers from Macquarie University and the University of Adelaide.

Read Full Article

Regeneus Ltd (ASX:RGS) Enrolment Complete and Positive Safety in Progenza Trial For Osteoarthritis

🕔5/16/2016 9:23:45 AM 2914

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced completion of enrolment of all 20 patients in the STEP trial. Further, a review of the cumulative study safety data by the study safety oversight committee identified no safety concerns.

Read Full Article
###

28,740 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 93) (Last 30 Days: 474) (Since Published: 15764) 

Markets ASX:RGS

Company Data

    Headquarters
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports

Presentations

Research Report

Social Media